PDF(Pubmed)
Abstract：
The novel coronavirus disease 2019 (COVID-19) has become a matter of international concern as the disease is spreading exponentially. Statistics showed that infected patients in China who received combined treatment of Traditional Chinese Medicine and modern medicine exhibited lower fatality rate and relatively better clinical outcomes. Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing-Gan Granule (JHQGG) have been recommended by China Food and Drug Administration for the treatment of COVID-19 and have played a vital role in the prevention of a variety of viral infections. Here, we desired to analyze the broad-spectrum anti-viral capacities of LHQWC and JHQGG, and to compare their pharmacological functions for rational clinical applications. Based on literature mining, we found that both LHQWC and JHQGG were endowed with multiple antiviral activities by both targeting viral life cycle and regulating host immune responses and inflammation. In addition, from literature analyzed, JHQGG is more potent in modulating viral life cycle, whereas LHQWC exhibits better efficacies in regulating host anti-viral responses. When translating into clinical applications, oral administration of LHQWC could be more beneficial for patients with insufficient immune functions or for patients with alleviated symptoms after treatment with JHQGG.
摘要：
新型冠状病毒病2019（COVID-19）已成为国际关注的问题，因为该疾病正在呈指数级传播。统计数据显示，中国接受中医和现代医学联合治疗的感染患者的病死率较低，临床预后相对较好。莲花清温胶囊（LHQWC）和金花清甘颗粒（JHQGG）均已被中国食品药品监督管理局推荐用于治疗COVID-19，并在预防COVID-19方面发挥了至关重要的作用。多种病毒感染。这里,我们希望分析LHQWC和JHQGG的广谱抗病毒能力，并比较其药理作用，以便临床合理应用。在文献挖掘的基础上，我们发现LHQWC和JHQGG通过靶向病毒生命周期和调节宿主免疫反应和炎症而被赋予多种抗病毒活性.此外,从文献分析，JHQGG在调节病毒生命周期方面更有效，而LHQWC在调节宿主抗病毒反应方面表现出更好的功效。当转化为临床应用时，口服LHQWC可能对免疫功能不足的患者或JHQGG治疗后症状缓解的患者更有益.
